You are here

  • Home
  • Archive
  • Volume 69, Issue 3
  • Treatment for Helicobacter pylori appears to reduce the incidence of gastric cancer: eradication effect or screening effect?

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Treatment for Helicobacter pylori appears to reduce the incidence of gastric cancer: eradication effect or screening effect?
  1. Yutaka Yamaji1,
  2. Yoshihiro Hirata2
  1. 1 Health Development Center, Tokyo Pharmaceutical Industry Health Insurance Society, Tokyo, Japan
  2. 2 Division of Advanced Genome Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
  1. Correspondence to Dr Yutaka Yamaji, Health Development Center, Tokyo Pharmaceutical Industry Health Insurance Society, Tokyo, Japan; yamaji-tky{at}umin.ac.jp

https://doi.org/10.1136/gutjnl-2018-318206

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read with interest the report by Doorakkers et al describing the effect of Helicobacter pylori eradication in preventing the development of non-cardia gastric adenocarcinoma in a population-based Swedish cohort.1 The authors used nationwide Swedish registries to investigate the incidence of gastric adenocarcinoma after H. pylori eradication treatment. Specifically, standardised incidence ratios (SIRs) were used to examine the incidence of gastric adenocarcinoma in individuals treated for H. pylori compared with a background population of corresponding age, sex and calendar year distribution. The time trend of the SIRs after H. pylori eradication was assessed for up to 7.5 years.

    The results showed that the risk of non-cardia gastric adenocarcinoma sharply decreased over time after …

    View Full Text

    Footnotes

    • Contributors The two authors have written, revised and approved the letter.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    • Patient consent for publication Not required.